Advertisement
Canada markets closed
  • S&P/TSX

    21,969.24
    +83.86 (+0.38%)
     
  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     
  • DOW

    38,239.66
    +153.86 (+0.40%)
     
  • CAD/USD

    0.7316
    -0.0007 (-0.09%)
     
  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     
  • Bitcoin CAD

    87,502.70
    -906.94 (-1.03%)
     
  • CMC Crypto 200

    1,383.71
    -12.82 (-0.95%)
     
  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     
  • RUSSELL 2000

    2,002.00
    +20.88 (+1.05%)
     
  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     
  • NASDAQ

    15,927.90
    +316.14 (+2.03%)
     
  • VOLATILITY

    15.03
    -0.34 (-2.21%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     

Extendicare Third Quarter 2022 Earnings: CA$0.041 loss per share (vs CA$0.027 profit in 3Q 2021)

Extendicare (TSE:EXE) Third Quarter 2022 Results

Key Financial Results

  • Revenue: CA$308.9m (flat on 3Q 2021).

  • Net loss: CA$4.36m (down by 282% from CA$2.40m profit in 3Q 2021).

  • CA$0.041 loss per share (down from CA$0.027 profit in 3Q 2021).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Extendicare Earnings Insights

Looking ahead, revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Healthcare industry in Canada.

Performance of the Canadian Healthcare industry.

The company's shares are up 1.7% from a week ago.

ADVERTISEMENT

Risk Analysis

Before we wrap up, we've discovered 5 warning signs for Extendicare (2 shouldn't be ignored!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here